



GB04/4367



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 28 OCT 2004

WIPO

PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 21 October 2004

BEST AVAILABLE COPY

THE PATENT OFFICE
14 OCT 2003
LONDON

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

N.90008 MN/SAR

150CT03 E844532-7 D00192

P01/7700 0.00 0324058.7

2. Patent application number

(The Patent Office will fill this part)

0324058.7

14 OCT 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

EXETER ANTIOXIDANT THERAPEUTICS LTD
The Innovation Centre
Rennes Drive
Exeter, Devon, EX4 4RN

Patents ADP number (if you know it)

8512733001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

DECONTAMINATION, DISINFECTION OR
STERILIZATION METHOD AND APPARTUS

5. Name of your agent (if you have one)

J. A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 South Square
Gray's Inn
London
WC1R 5JJ

Patents ADP number (if you know it)

26001

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Yes

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	0
Description	16
Claim(s)	3
Abstract	1
Drawing(s)	2 + 2 <i>ans</i>

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for a preliminary examination and search (Patents Form 9/77)	1
Request for a substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

J.A. Kemp
J.A. KEMP & CO.

Date 14 October 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

M. Nicholls
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

DUPLICATE

-1-

DECONTAMINATION, DISINFECTION OR STERILIZATION METHOD AND APPARATUS

The present invention relates to a method of and apparatus for decontaminating,
5 disinfecting or sterilizing articles in particular by use of an electrolytic system with
an oxygenated electrolyte. The method is particularly suitable for the sterilization of
medical devices such as surgical instruments.

Decontamination of an instrument represents a combination of processes used to
10 render the instrument safe for re-use. Although applicable to a variety of fields of
industry, decontamination is of particular importance in the field of healthcare.

In general, the steps involved in a process of decontamination of a medical
instrument are cleaning, disinfection and sterilization. Cleaning is a necessary first
15 step in the decontamination, since it removes organic matter, which, in addition to
posing a health risk in its own right, can inhibit the later disinfection and sterilization
steps. The next step in the process is disinfection, which aims to remove or destroy
pathogenic microorganisms, with the exception of bacterial spores. Disinfection is
typically achieved through either automated washing and heating processes or by the
20 application of chemicals. There are a number of chemical disinfectants which are
commonly used which include general purpose detergents, such as household
detergents (e.g. dishwashing liquid), chlorine preparations, (e.g. sodium
hypochlorite) and alcohol preparations (e.g. 70% isopropyl alcohol). However, a
number of these preparations, in particular the chloride-containing disinfectants, can
25 cause corrosion of surgical instruments. Disinfection can also be achieved using
washer/disinfectors, which use a combination of automated cleaning and heat to
remove microorganisms. The final step in the decontamination is sterilization which
is aimed at the, ideally complete, removal of, ideally all, organisms from the medical
instrument, including bacterial spores. Sterilization is generally performed using
30 steam and requires contact between all surfaces of the instrument to be sterilized and

steam at a specified pressure for a specified period of time. However, sterilization can also cause corrosion of a surgical instrument, particularly if tap water is used in the steam sterilizer. Of course, it is to be understood that disinfection and sterilization are not only performed within a process of decontamination and may be
5 processes performed in their own right.

Decontamination of medical equipment is crucial to the minimisation of the risk of hospital acquired infections (HAI), for example MRSA. A further example of such infections are transmissible spongiform encephalopathies (TSEs) or "prion diseases"
10 which are neurodegenerative disorders of the central nervous system that lead to motor dysfunction, dementia and eventually death. An example of such a TSE is Creutzfeldt Jakob Disease (CJD). There is no known risk of TSE transmission through normal clinical or social contact with an infected person, however, patients have been infected when undergoing neurosurgery, corneal and dura matter
15 transplantation as well as injection of human growth hormone (Decontamination of Surgical Instruments and Other Medical Devices - *Report of a Scottish Executive Health Department Working Group* February 2001).

Bovine spongiform encephalopathy (BSE) and variant CJD (vCJD) are also examples
20 of TSEs. The agent that causes BSE and vCJD has not yet been verified but it is known that an improperly folded form of a membrane prion protein (PrP) is involved. This disease-specific form of PrP, termed PrP^{Sc}, has been found in the tonsils, spleen and lymph nodes and CNS of patients who have died as a result of contracting vCJD.

25 Prion proteins are an issue in medical decontamination because they have extreme resistance to conventional sterilisation techniques and a tendency to bind to the surfaces of metal and plastic without loss of infectivity (*PNAS Colloquium*; 2002; 99, suppl.4; 16378-16383). Sterilisation of PrP^{Sc} by heat currently involves exposure of
30 the protein to steam at 134°C for 18 minutes in a porous load autoclave. However, it

has been suggested that longer exposure times may be required, and even so, complete inactivation may not be possible by this method. In a case that highlights the infectivity of prion proteins, an electrode that had previously been inserted into the cortex of an undiagnosed CJD-infected patient was subjected to a

5 decontamination procedure that involved treatment with benzene, 70% ethanol and formaldehyde vapour (*J. Neurol. Neurosurg. Psychiatry*; 1994; 57, 757-758). This same electrode was subsequently used on two patients, both of whom developed CJD within two years of treatment. The electrode had been cleaned as above after each use. The electrode, recognised as the culprit, was then inserted into the brain of a
10 chimpanzee, where it also caused spongiform encephalopathy. This investigation showed that the electrode continued to possess infectious prion proteins even after several years and numerous attempts at sterilization. A method of sterilization which was able to remove prion proteins from the surface of a medical instrument would therefore represent an significant improvement over the prior art.

15

It is an object of the present invention to provide an improved method of decontamination, disinfection or sterilization.

According to a first aspect, the present invention provides a method of
20 decontaminating, disinfecting or sterilizing an article which method comprises placing the article in an electrolytic system with an oxygenated electrolyte and applying a potential difference to the electrolytic system. It is believed that contaminants, for example contaminating biological matter, can be effectively removed from an article using the method of the present invention. It is also believed
25 that the method serves to degrade, or otherwise render ineffective, contaminants present on the surface or contaminants that are present in the electrolyte (for example contaminants that become removed from the surface during the method). It is further believed that the method of the present invention can inhibit re-adhesion of contaminants to the article. The method of the present invention is particularly
30 suitable as a method of sterilizing an article.

The method of the present invention is suitable for the decontamination, disinfection or sterilization of any article. However, it is particularly suitable for the decontamination, disinfection or sterilization of medical instruments, for example surgical instruments or dental instruments. The medical instruments are typically medical conductive instruments such as medical instruments which comprise metal. Preferably, the medical instrument is a surgical instrument. Examples of such surgical instruments are scalpels, electrodes and surgical screws.

- 10 The electrolyte that can be used in the electrolytic system of the present invention can be any electrolyte within which oxygen may be reduced. The skilled person would be aware of electrolytes which are suitable for this purpose. Typical electrolytes are aqueous solutions of ionic salts. Examples of such electrolytes are aqueous solutions of potassium hydroxide, sodium phosphate, sodium chloride, sodium sulphate, sodium hydrogen carbonate, orthoborate or citrate. Preferred electrolytes are environmentally friendly electrolytes such as aqueous solutions of sodium phosphate, sodium chloride, sodium sulphate, sodium hydrogen carbonate, orthoborate or citrate or mixtures thereof. A particularly preferred electrolyte is an aqueous solution of sodium hydrogen carbonate.

20

- The pH of the electrolyte can affect the reduction of oxygen in the electrolytic system. For example, it is known that oxygen can undergo electro-reduction to produce the superoxide ion. This superoxide ion is a basic species and its stability decreases with pH. It is therefore preferred that the electrolyte is either neutral or alkaline. A typical range for the pH for the electrolyte is from 7 to 11. Due to environmental considerations, it is preferred that the pH of the electrolyte is substantially pH 7.

The present inventors have found that the presence of impurities in the electrolyte can reduce the rate of oxygen reduction. In light of this, when using aqueous electrolytes, it is preferable to use deionised water to prepare the electrolytic solution.

- 5 However, the present inventors have also found that additives in the electrolyte can, in some cases, enhance the reduction of oxygen in the electrolytic system. An example of such an additive is detergent and the present inventors have found that a detergent concentration of 0.1ml per ml of electrolyte or greater can enhance the increase the rate of reduction of oxygen. The present invention thus also relates to
10 electrolytes which comprise additives wherein said additives enhance the reduction of oxygen in the electrolytic system

- Oxygenation of the electrolyte is achieved by any method suitable for introducing oxygen (preferably molecular oxygen) into the electrolytic solution. Typical methods
15 include bubbling an oxygen-containing gas (preferably a molecular oxygen-containing gas) through the electrolyte. Such a method is typically performed until the electrolyte is saturated with oxygen or the oxygen containing gas, although complete saturation of the electrolyte may not be necessary. It is envisaged that any oxygen-containing gas could be used for this purpose, however, it would typically be
20 air. A precursor, which provides oxygen during the conditions of the reaction, could also be used to oxygenate the electrolyte.

- Typically, the oxygen content in the electrolyte, in terms of the saturation level of oxygen, is from 1 to 100%. Preferably, the oxygen content is from 25 to 100%.
25 More preferably, the oxygen content is from 50 to 100%. Particularly preferably, the oxygen content is 75 to 100%.

The electrolyte is typically oxygenated before a voltage is applied to the electrolytic cell. However, oxygen can be introduced into the electrolyte during electrolysis.

The potential difference applied to the electrolytic system is typically a potential sufficient to reduce the oxygen in the oxygenated electrolyte. Generally, the potential difference applied to the system is less than that sufficient to reduce water to hydrogen gas. The potential difference which is sufficient to reduce the oxygen in the oxygenated electrolyte will be dependent upon numerous factors including the nature of the electrolyte, the pH of the electrolyte and the cathode. However, in general the range of the potential difference will be from -1.50 to +0.25V. A preferred range for the potential difference is -1.25 to -0.5V. A more preferred range is -1.0 to -0.8V. As an example, for a polished stainless steel cathode in an alkaline solution the range of the potential difference for oxygen reduction is -0.2 to -0.9V.

The method of the present invention can be performed at any temperature generally used for electrolytic systems. An example of a suitable temperature range is 10 to 75°C. A preferred temperature range is 15 to 50°C. It is envisaged that the method will generally be performed at room temperature.

The time for which the potential difference is applied to the electrolytic system will be dependent upon many factors including the nature of the electrolytic system, the voltage applied and the oxygen content of the electrolyte. However, it is envisaged that the potential difference will be applied for a time of up to about 36 hours. A preferred time limit is from 6 to 30 hours and a particularly preferred time limit is from 8 to 24 hours.

The cathode of the electrolytic system may be made of any suitable conducting material that will allow oxygen to be reduced on its surface. Examples of such materials are stainless steel and related alloys.

Reactive oxygen species may be produced by the method above using an electrolytic system and an oxygenated electrolyte. Another aspect of the present invention provides the use of a reactive oxygen species in the decontamination, disinfection or

sterilization of an article. In particular, the present invention provides the use of a reactive oxygen species in the sterilization of an article. Preferred reactive oxygen species are one or more of the superoxide ion ($O_2^{\bullet -}$), the hydroxy radical (OH^{\bullet}) and hydrogen peroxide (H_2O_2). Particularly preferred is when one of the reactive oxygen
5 species is the superoxide ion. It is most preferred when the reactive oxygen species is the superoxide ion.

A further aspect of the present invention provides a decontamination, disinfection or sterilization apparatus which comprises an electrolytic system with an oxygenated
10 electrolyte. The present invention also provides a decontamination, disinfection or sterilization apparatus which comprises an electrolytic system which, in use, comprises an oxygenated electrolyte. The present invention further provides such an apparatus wherein the cathode of the electrolytic system is the article to be sterilized. The present invention also provides a decontamination, disinfection or sterilization
15 apparatus for performing a method of decontamination, disinfection or sterilization as herein described.

The invention will be further described by way of example, with reference to the accompanying drawings, in which :-

20

Figure 1 shows DTNB assays for glutathione for a control, an aerated and a deaerated electrolyte; and

Figure 2 schematically illustrates an electrolytic system in accordance with one
25 embodiment of the invention.

Figure 2 schematically shows an electrolytic system which comprises: a power source 1 for applying a potential difference to the electrolytic system; an anode 2; a cathode 3; an oxygenated electrolyte 4; and a vessel 5.

30

The anode 2 may be made of any suitable conducting material. Examples of suitable materials include Nobel metals, such as platinum, and graphite.

In the electro-reduction of oxygen in an electrolytic system, oxygen is typically
5 reduced at the cathode 3. However, the reduced oxygen species produced at the
cathode 3 can be free in the electrolyte 4 and can also undergo reactions in the
electrolyte 4 to produce further oxygen electro-reduction species. The method of the
present invention can therefore be performed by placing the article to be sterilized
into the electrolyte 4 of the electrolytic system. However, in relation to the
10 sterilization of a conductive or other metallic article, since the reduction of oxygen
can occur at the surface of the cathode 3, it is a preferred embodiment of the present
invention that the instrument to be sterilized is used as the cathode 3. It is to be
understood that all or part of the conductive or other metallic article can comprise a
conductive or metallic material. Furthermore, all or part of the surface of the
15 conductive or other metallic article can comprise a conductive or metallic material.
This embodiment is particularly suitable for stainless steel articles, for example
stainless steel surgical instruments.

Surgical instruments typically comprise stainless steel. There are three types of
20 stainless steel used in the manufacture of surgical instruments, martensitic, austenitic
and ferritic. Martensitic stainless steel consists of iron (72-89.3%), chromium (10.5-
18%) and carbon (0.2-1%). Martensitic stainless steel is moderately resistant to
corrosion, and is used to make instruments that are required to have cutting edges,
and to be strong and resistant to wear. Examples of martensitic stainless steel
25 surgical instruments include surgical needle holders and dental scalers.

Austenitic stainless steel consists of iron (62-78%), chromium (16-26%) and nickel
(6-12%). This type of stainless steel is used to manufacture medical instruments that
require good corrosion resistance and moderate strength. Examples of austenitic
30 stainless steel medical instruments include hypodermic needles and dental impression

trays. Ferritic stainless steel consists of iron (approximately 82-87%), chromium (12.5% or 17%) and nickel (typically <1%). This type of stainless steel finds relatively little use in the manufacture of medical instruments. Examples of ferritic stainless steel medical instruments include medical devices with screw heads and
5 solid handles for instruments.

In this embodiment of the present invention, when a potential difference is applied to electrolytic system, the oxygen in the oxygenated electrolyte can undergo a series of reactions which produce reactive oxygen species. Examples of such reactive oxygen
10 species are the superoxide ion ($O_2^{\cdot-}$), the hydroxy radical (OH^{\cdot}) and hydrogen peroxide (H_2O_2). The efficacy of the method of decontamination, disinfection or sterilization described herein is presently ascribed to the reactive oxygen species which are produced under the conditions of the reaction.

EXAMPLES

Materials and Methods

Surgical instrument electrode

- 5 A 2-inch section of a surgical tissue clamp was cut and used as the surgical instrument electrode.

Electrochemistry

The electrochemistry machine used was a BAS-50W Voltammetric analyser.

10

Chemicals

All chemicals were of the highest purity available and were acquired from Sigma-Aldrich, unless otherwise stated.

15 Mass spectrometry

All mass spectrometry was performed on a Micromass LC analyser. All mass spectrometry was done in electrospray positive mode, with a cone voltage of 30V.

Electrolysis

- 20 **Cyclic Voltammetry.** All cyclic Voltammetry was performed by the following method. All potentials are quoted against the Ag/AgCl reference electrode, unless otherwise stated.

- A 20 ml aliquot of electrolyte was used in a standard electrochemical cell. The working electrode was polished with polishing alumina before each use. The
25 auxiliary electrode was either a graphite rod (6 mm diameter), or a platinum coil. The reference electrode was Ag/AgCl. The initial scan direction was negative. A magnetic stirrer was used to stir the solution. For deaerated solutions, nitrogen was passed through the solution for one hour before electrolysis. After one hour, the nitrogen outlet tube was removed from the electrolyte, and placed over its surface.

This maintained a blanket of nitrogen over the electrolyte surface throughout electrolysis.

Glutathione degradation – assessment by DTNB assay

- 5 Bulk electrolysis was run for 90 minutes. A 100 μ M sample was removed from the electrolysis cell every 15 minutes. This sample was added to a cuvette containing 1 mM ethylenediamine-tetraacetic acid (EDTA) and 100 μ M 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) in deionised water. The absorbance was read at 412 nm. A control was left standing at room temperature for 90 minutes, and then 100 μ l was added to the EDTA and DNTB solution and the absorbance was read at 412 nm.

Glutathione degradation – assessment by mass spectrometry

- 10 μ l of 100 mM glutathione stock solution was added to a bulk electrolysis cell and run as described for 90 minutes. The initial concentration of glutathione was 50 μ M.
- 15 A sample was then removed and added to an equal amount of a solution of 49.5% acetonitrile + 49.5 % deionised water + 1% formic acid. The final GSH concentration was 200 nM. A GSH control was also prepared, so that the final GSH concentration was 200 nM. These solutions were run in the electrospray mass spectrometer.

20 Assessment of myoglobin degradation by mass spectrometry

- Myoglobin stock solutions were made to 10 mg/ml concentration and de-salted on a PD-10 column flushed with deionised water.
- 1 ml of a 10 mg/ml myoglobin stock solution solution was added to 19 ml electrolyte.
- 25 Bulk electrolysis was run as described for 8 hours. A sample was removed every hour. One part protein solution was added to two parts of a 49.5% acetonitrile + 49.5 % deionised water + 1% formic acid solution. A control was allowed to sit at room temperature. The control was made up of 1 ml stock myoglobin solution and 19 ml NaHCO_3 pH 7, 50 mM. The solutions were run in the electrospray mass spectrometer.
- 30 The control solution and all protein samples were stored at -20°C until

use.

Assessment of myoglobin degradation by SDS-PAGE

A 15% acrylamide gel was prepared from the following:

5

Resolving gel:

4.24 ml bisacrylamide

3.995 ml Resolving buffer mix

1 ml ammonium persulphate

10 10 μ l TEMED

4.769 ml Water

Stacking gel:

0.3034 ml bisacrylamide

15 2.03 ml Stacking buffer mix

0.3 ml ammonium persulphate

4 μ l TEMED

0.669 ml water

20 The gels were run at 100 mV, stained with coomassie blue and then destained with destaining solution

Bulk Electrolysis on the surgical instrument

25 All bulk electrolysis experiments were performed as follows. The working electrode was the polished surgical instrument. The magnetic stirrer was set to a rate of 700 rpm. The auxiliary electrode was a graphite rod. The fixed potential was -900 mV. 50 mM NaHCO₃, pH 7, electrolyte was used.

Example 1

Glutathione degradation

Assessment of glutathione degradation by the DTNB assay

Glutathione (GSH) is a tripeptide consisting of cysteine, glycine and glutamate. 5,5'-Dithiobis(2-nitrobenzoic acid) (DTNB) reacts with SH groups to produce 5-

5 mercapto-2-nitrobenzoic acid, which absorbs light at wavelength 412 nm. As GSH has a sulfhydryl group, DTNB can be used to assay the amount of GSH present in a sample. In this assay, glutathione was added to the electrolyte so that the final GSH concentration was 50 μ M. The surgical instrument was used as the working electrode, and was held at a constant potential of -900 mV for 90 minutes. A sample was removed from the electrochemical cell at 15-minute intervals and used in the DTNB assay. This was done in triplicate for both aerated and deaerated solution. Controls containing glutathione in the electrolyte were left to stand at room temperature for 1 hour. Figure 1 compares the results of the DTNB assays for aerated and deaerated solutions.

15

The results of the DTNB assay show a clear difference between the aerated and deaerated solutions. The results of the assay for the aerated solution indicate that the surgical instrument working electrode degrades glutathione in NaHCO_3 pH 7. The absorbance decreases linearly until after about 40 minutes, when it begins to plateau.

20 This is consistent with increasing production of reactive oxygen species by the reduction of oxygen in the electrolyte, until a maximal rate is achieved, limited by mass transport of both O_2 and GSH to the working electrode. In the deaerated solution, some degradation of glutathione seems to occur, but at a rate only slightly faster than the control. The graph of absorbance against time for the deaerated solution closely follows the graph for the control. This suggests that either the
25 degassing was incomplete, and some oxygen remained in the electrolyte, or that GSH is oxidised to some degree by a process not involving oxygen at the auxiliary electrode.

Assessment of glutathione degradation by mass spectrometry

Glutathione (GSH) was added to 50 mM $\text{NaHCO}_{3(\text{aq})}$ pH 7 electrolyte so that the final GSH concentration was 50 μM . The surgical instrument was used as the working electrode, and was held at a constant potential of -900 mV for 90 minutes. At 90
5 minutes, a sample was removed from the electrochemical cell and run in an ES mass spectrometer. A control containing glutathione in the electrolyte was left to stand at room temperature for 90 minutes.

The molecular weight of glutathione is 307 and the control solution showed a peak at
10 approximately m/z 308 due to protonated glutathione. This peak for glutathione is present in the mass spectrum for the control solution, but absent from the mass spectrum for the aerated solution. This indicates that glutathione is degraded by oxygen reduction at -900 mV on the surgical instrument electrode in aqueous NaHCO_3 pH 7 electrolyte. A peak also appeared at approximately 615 due to GSSG, the oxidised form of
15 glutathione, which is present as a small proportion of total peptide.

Example 2

Myoglobin degradation

Assessment of myoglobin degradation by mass spectrometry

20 1 ml of a 10 mg/ml myoglobin stock solution was added to 19 ml electrolyte. Bulk electrolysis was run for 8 hours with the surgical instrument as the working electrode, at a potential of -900 mV. A sample was removed every hour and stored in the fridge. This was done for both aerated and deaerated solution. A control containing myoglobin in NaHCO_3 (pH7) was allowed to sit at room temperature for 8 hours. The
25 control was made up to the same concentration as the sample. Following electrolysis, the solutions were run in an Electron spray mass spectrometer.

In the mass spectrum of the stock solution, peaks appeared between m/z 700 and m/z 1600 corresponding to differently protonated forms of myoglobin. The molecular
30 mass of horse heart myoglobin is approximately 17,000 g/mol. The peaks at m/z 707,

734, 771, 808, 849, 893, 943, 998, 1060, 1131, 1138, 1219, 1319 and 1413 correspond to myoglobin protonated between 24 - 12 times, respectively.

There was a decrease in the peak heights corresponding to myoglobin in the control, compared to the stock solution. Additional peaks were also observed between m/z 600 and m/z 94 in the control mass spectrum, which were not present in the mass spectrum for the stock solution. These peaks could correspond to the breakdown products of myoglobin in the control. In particular, there were relatively large peaks at m/z 91 and 227 which were absent from the control spectrum. It is suggested that these differences in the mass spectra for the stock and control solutions were due to normal degradation seen when freeze-thawing proteins.

The mass spectra for the deaerated solution indicated that even after eight hours of bulk electrolysis, there was only a small relative difference compared to the control. The mass spectra for the aerated solution, on the other hand, clearly indicated a large relative difference between the samples removed from bulk electrolysis and the control. After eight hours of electrolysis at -900 mV, the myoglobin peak had almost completely disappeared. Comparison of the spectra for the 8-hour samples from the aerated and deaerated solutions indicates that such extensive degradation occurs only in the aerated solution.

Assessment of myoglobin degradation by SDS-PAGE

The same samples used for the mass spectrometric analysis were also analysed by polyacrylamide gel electrophoresis (PAGE).

The size markers used were broad range size markers, consisting of nine peptides with molecular weights of 225, 150, 100, 75, 50, 35, 25, 15 and 10 kDa.

There was a clear difference between the gels for the deaerated and aerated solutions. The gel for the deaerated solution indicated that after incubation for eight hours in the electrolysis cell, there is little observable difference in the intensity of the myoglobin bands compared to the control. In the gel for the aerated solution, there is a clear

decrease in intensity after five hours compared to the control and to the equivalent lane in the gel for the deaerated solution. The intensity of the bands decreased even further for the 6, 7 and 8- hour samples. After electrolysis for 8 hours in aerated electrolyte, the sample gives only a very faint band corresponding to intact
5 myoglobin, compared to the control.

CLAIMS

1. A method of decontaminating, disinfecting or sterilizing an article which method comprises placing the article in an electrolytic system with an oxygenated electrolyte and applying a potential difference to the electrolytic system.
2. A method according to claim 1 wherein the method is a method of sterilizing an article.
3. A method according to either claim 1 or claim 2 wherein the article is a medical instrument.
4. A method according to any one of the preceding claims wherein the article is a surgical instrument
5. A method according to any one of the preceding claims wherein the article comprises stainless steel.
6. A method according to any one of the preceding claims wherein the article comprises the cathode of the electrolytic system.
7. A method according to any one of the preceding claims wherein the electrolyte is an aqueous solution of sodium phosphate, sodium chloride, sodium sulphate, sodium hydrogen carbonate, orthoborate or citrate.
8. A method according to claim 7 wherein the electrolyte is an aqueous solution of sodium hydrogen carbonate.
9. A method according to any one of the preceding claims wherein the

electrolyte is either neutral or alkaline.

10. A method according to claim 9 wherein the pH of the electrolyte is substantially 7.
 - 5 11. A method according to any one of the preceding claims wherein the electrolyte is aerated prior to use.
 12. A method according to any one of the preceding claims wherein the
10 electrolyte is aerated during the electrolysis.
 13. A method according to any one of the preceding claims wherein the oxygen content of the oxygenated electrolyte is from 1 to 100%.
 - 15 14. A method according to claim 13 wherein the oxygen content of the oxygenated electrolyte is from 50 to 100%.
 15. A method according to any one of the preceding claims wherein the potential difference applied to the electrolytic system is from -1.50 to 0.25 V.
 - 20 16. A method according to claim 14 wherein the potential difference is from -1.25 to -0.5 V.
 17. A method according to any one of the preceding claims wherein the potential
25 difference is applied to the electrolytic system for up to 36 hours.
 18. A method according to any one of claims 16 wherein the potential is applied for 6 to 24 hours.
 - 30 19. Use of a reactive oxygen species in the decontamination, disinfection or
-

sterilization of an article.

20. Use according to claim 19 in the sterilization of an article.
- 5 21. Use according to either claim 19 or claim 20 wherein the reactive oxygen species comprises one or more of the superoxide ion ($O_2^{\bullet-}$), the hydroxy radical (OH^{\bullet}) and hydrogen peroxide (H_2O_2).
22. Use according to claim 21 wherein one of the reactive oxygen species is the
10 superoxide ion.
23. A decontamination, disinfection or sterilization apparatus which comprises an electrolytic system with an oxygenated electrolyte.
- 15 24. A decontamination, disinfection or sterilization apparatus which comprises an electrolytic system which, in use, comprises an oxygenated electrolyte.
25. An apparatus according to either claim 23 or claim 24 wherein the cathode of the electrolytic system is the article to be sterilized.
20
26. A decontamination, disinfection or sterilization apparatus for performing a method as described in any one of claims 1 to 18.

ABSTRACT

**DECONTAMINATION, DISINFECTION OR STERILIZATION
METHOD AND APPARATUS**

5

A method of decontaminating, disinfecting or sterilizing an article which method comprises placing the article in an electrolytic system with an oxygenated electrolyte and applying a potential difference to the electrolytic system. The method is particularly suitable for the sterilization of stainless steel surgical instruments

10 wherein the instrument comprises the cathode in the electrolytic system.

1/2




Figure 1




Figure 2

PCT/GB2004/004367



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.